Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)

NCT02273661 is registered in ClinicalTrials.gov with Poitiers University Hospital as lead sponsor.

NCT NCT02273661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02273661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)
Lead sponsor
Poitiers University Hospital
Phase
Phase 2
Overall status
Completed
Start date
November 19, 2014
Completion date
June 28, 2019
Enrollment
174 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic bronchopulmonary aspergillosis